Li Y, Drabison T, Nepal M, Ho R, Leblanc A, Gibson A
JCI Insight. 2023; 8(14).
PMID: 37347545
PMC: 10443802.
DOI: 10.1172/jci.insight.164646.
Tsai C, Lin Y, Li Y, Ho T, Thuong L, Liu Y
Int J Mol Sci. 2021; 22(17).
PMID: 34502166
PMC: 8430591.
DOI: 10.3390/ijms22179257.
Nicolai J, Thevelin L, Bing Q, Stieger B, Chanteux H, Augustijns P
Pharm Res. 2017; 34(11):2336-2348.
PMID: 28828541
DOI: 10.1007/s11095-017-2241-0.
Starobova H, Vetter I
Front Mol Neurosci. 2017; 10:174.
PMID: 28620280
PMC: 5450696.
DOI: 10.3389/fnmol.2017.00174.
Bradfield S, Sandler E, Geller T, Tamura R, Krischer J
Pediatr Blood Cancer. 2014; 62(6):1004-10.
PMID: 25545757
PMC: 4405446.
DOI: 10.1002/pbc.25384.
Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.
Chiang C, Song E, Yang V, Chao C
Biochem J. 1994; 301 ( Pt 3):759-64.
PMID: 7914401
PMC: 1137052.
DOI: 10.1042/bj3010759.
Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.
Hill B, Whelan R
Cancer Chemother Pharmacol. 1982; 8(2):163-9.
PMID: 7105380
DOI: 10.1007/BF00255477.
Collateral sensitivity of a methotrexate-resistant L1210 cell line to the vinca alkaloids.
Poppitt D, McGown A, Fox B
Cancer Chemother Pharmacol. 1984; 13(1):43-6.
PMID: 6733841
DOI: 10.1007/BF00401446.
Improved tolerance of vincristine by glutamic acid. A preliminary report.
Jackson Jr D, Pope E, Case L, Wells H, White D, Cooper M
J Neurooncol. 1984; 2(3):219-22.
PMID: 6150069
DOI: 10.1007/BF00253273.
Decreased retention of vinca alkaloids in chronic lymphatic leukemia cells from refractory patients.
Beksac M, Peterson C, Reizenstein P
Cancer Chemother Pharmacol. 1985; 15(1):72-5.
PMID: 4006052
DOI: 10.1007/BF00257299.
Membrane transport changes in an adriamycin-resistant murine leukemia cell line and in its sensitive parental cell line.
Bose R, Lam H
Cancer Chemother Pharmacol. 1988; 21(1):14-8.
PMID: 3342461
DOI: 10.1007/BF00262731.
5-Fluorouracil containing combinations in murine tumor systems.
Corbett T, Bissery M, Mucci-LoRusso P, Polin L
Invest New Drugs. 1989; 7(1):37-49.
PMID: 2661481
DOI: 10.1007/BF00178190.
Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro.
Kolber M, Hill P
Cancer Chemother Pharmacol. 1992; 30(4):286-90.
PMID: 1643696
DOI: 10.1007/BF00686297.
Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
Pierre A, Perez V, Leonce S, Boutin J, Hautefaye P, Lavielle G
Cancer Chemother Pharmacol. 1992; 29(5):367-74.
PMID: 1551175
DOI: 10.1007/BF00686005.
Preclinical and clinical pharmacology of vinca alkaloids.
Zhou X, Rahmani R
Drugs. 1992; 44 Suppl 4:1-16; discussion 66-9.
PMID: 1283846
DOI: 10.2165/00003495-199200444-00002.
Antineoplastic drugs: clinical pharmacology and therapeutic use.
Bender R, Zwelling L, Doroshow J, Locker G, Hande K, Murinson D
Drugs. 1978; 16(1):46-87.
PMID: 78795
DOI: 10.2165/00003495-197816010-00003.
